Introduction {#Sec1}
============

The 2008 World Health Organization classification defines chronic lymphocytic leukemia (CLL) as a low-grade lymphoproliferative neoplasm with ≥5 × 10^9^/L clonal B-cells in the peripheral circulation that express CD5, CD19, dimCD20, and CD23^[@CR1]^. All cases of CLL are preceded by its pre-malignant counterpart called monoclonal B-cell lymphocytosis (MBL; defined as \<5 × 10^9^/L clonal B-cells in the absence of lymphadenopathy, organomegaly, and cytopenias)^[@CR2]^. MBL can be detected in \~5% of healthy individuals \>40 years of age, making it one of the most common premalignant conditions in humans. Several groups have reported the risk of progression from MBL to CLL requiring therapy is \~1--2% per year^[@CR3],[@CR4]^. Individuals with MBL and early-stage asymptomatic CLL who do not meet the 2018 International Workshop on CLL \[IWCLL\] criteria to initiate therapy should be offered close follow-up ("wait and watch")^[@CR5]^. The introduction of chemoimmunotherapy (such as fludarabine, cyclophosphamide, and rituximab \[FCR\]), and bendamustine and rituximab \[BR\]^[@CR6],[@CR7]^, and more recently novel agents such as ibrutinib (Bruton tyrosine kinase inhibitor)^[@CR8]^, idelalisib (phosphatidylinositol-3-kinase δ inhibitor)^[@CR9]^, and venetoclax (BCL-2 inhibitor)^[@CR10]^ has revolutionized the management of CLL. This review will focus on the current approach to risk stratification and management of patients with CLL. Although this schema can be used for CLL patients worldwide, the limited availability of many novel agents outside the US may limit its broader applicability.

Contemporary risk stratification in CLL {#Sec2}
=======================================

There is a plethora of prognostic markers that help risk stratify CLL patients. Since the initial description of the Rai^[@CR11]^ and Binet^[@CR12]^ staging systems more than 4 decades ago, there have been tremendous advances in our understanding of the prognostic factors that predict time to first therapy and overall survival (OS) in CLL. These factors include simple laboratory tests (such as lymphocyte doubling time and lactate dehydrogenase), serum-based tests (such as beta-2 microglobulin and thymidine kinase)^[@CR13]^, and flow-cytometry based tests (such as expression of CD38, ZAP-70, and CD49d)^[@CR14],[@CR15]^. In 1999, two independent groups reported that CLL patients with higher degrees of somatic mutation in the immunoglobulin heavy chain variable gene (*IGHV*) experienced longer OS^[@CR16],[@CR17]^. Patients with mutated *IGHV* (defined as a greater than 2% difference from the germline sequence) had a median OS of \>20 years compared to those with unmutated *IGHV* who had median OS of 8 years. Although G-banding techniques detected chromosomal abnormalities in \~50% patients with CLL^[@CR18]^, the introduction of FISH to evaluate for cytogenetic defects in non-dividing cells led Dohner and colleagues to propose a new prognostic model in CLL. Using a hierarchical classification scheme, they demonstrated that patients with del17p13 had the shortest OS (\~3 years), followed by patients with del11q23 (\~6.5 years), trisomy 12 (\~9.2 years), negative FISH (\~9.5 years), and del13q14 (\~11 years)^[@CR19]^. Somatic mutations detected by next-generation sequencing showed that genes involved in DNA damage and cell cycle control (*ATM, TP53, RB1, BIRC3*), Notch signaling (*NOTCH1, NOTCH2, FBXW7*), cytokine signaling (NRAS, KRAS, BRAF), inflammatory pathways (*MYD88, DDX3X, MAPK1*), and spliceosome machinery (*SF3B1*) were recurrently mutated in CLL^[@CR20]^. Although the individual role of each of these genes in the pathogenesis and outcomes of CLL is currently being investigated, there is convincing data to show that CLL patients who harbor *NOTCH1* mutation (mostly occurring in patients with trisomy 12), *SF3B1* mutation (mostly occurring in patients with del13q14), and those with *TP53* mutation experience a shorter time to first therapy, progression-free survival (PFS), and OS^[@CR20]--[@CR25]^. In addition to these standard tests, other factors such as detection of subclonal mutations, micro-RNA signatures, B-cell receptor stereotypy, *IGHV* gene family usage, telomere length, and many others have been shown to provide important information about time to first therapy and OS in CLL patients^[@CR26]^.

Since these prognostic markers may offer a discrepant prognosis in the same patient (i.e., some suggest a shorter time to first therapy and OS whereas others do not), many attempts have been made to integrate these into a combined risk score^[@CR27]--[@CR29]^. The most recent effort---the CLL International Prognostic Index (CLL-IPI)---studied \~28 prognostic variables among \~3400 patients treated on clinical trials across the world, and was validated in two independent cohorts of patients, including from Mayo Clinic and the Scandinavian CLL cohort^[@CR30]^. Five factors were independently found to be associated with OS, including age \>65 years, Rai stage I--IV, serum beta-2 microglobulin \>3.5 mg/L, unmutated *IGHV* genes, and del17p by FISH or *TP53* mutation (Table [1](#Tab1){ref-type="table"}). Four risk groups (low, intermediate, high, and very-high risk) with different 5-year OS (93%, 79%, 63%, and 23%, respectively) were identified. There are several limitations to the CLL-IPI: (a) it does not include patients treated on novel agents; (b) it does not include other important prognostic variables such as somatic genetic mutations detected by next-generation sequencing and patient comorbidities; and (c) although the CLL-IPI was primarily developed to predict OS, it is generally applied in predicting time to first therapy in newly diagnosed previously untreated CLL patients (given the rapid adoption of novel agents in the management of CLL). The 5-year treatment-free survival in the Mayo validation cohort of previously untreated patients in the low, intermediate, high, and very-high risk CLL-IPI groups was 78%, 54%, 32%, and 0%, respectively. Other studies have also confirmed the ability of the CLL-IPI risk score in predicting time to first therapy in previously untreated CLL patients^[@CR31]--[@CR33]^.Table 1The CLL-International Prognostic Index^[@CR30]^Prognostic factorPointsDel17p on FISH or *TP53* mutation4Unmutated *IGHV* genes2Serum β2 microglobulin \>3.5 mg/L2Rai stage I--IV1Age \>65 years1Cumulative CLL-IPI scoreRisk category5-year TFS^a^0--1Low risk78%2--3Intermediate risk54%4--6High risk32%7--10Very high risk0%*FISH* fluorescence in situ hybridization, *IGHV* immunoglobulin heavy chain gene, *TFS* treatment-free survival^a^For the Mayo validation cohort

Minimal residual disease (MRD) at the end of CLL therapy is a powerful prognostic tool that predicts time to next therapy and OS in many studies, both in the chemoimmunotherapy and the novel agent era^[@CR34]--[@CR36]^. The 2018 IWCLL guidelines suggest using either multiparameter flow cytometry or allele-specific oligonucleotide polymerase chain reaction to detect MRD at 0.01% level (i.e., 1 leukemic cell in 10,000 leukocytes). An important limitation of using MRD as a biomarker in all CLL patients is that it cannot be used to predict outcomes in patients who are in the "wait and watch" asymptomatic phase of their disease.

Management of previously untreated CLL {#Sec3}
======================================

The vast majority of CLL patients have early-stage asymptomatic disease at diagnosis. Only those patients who meet the 2018 IWCLL criteria^[@CR5]^ for initiation of therapy (Table [2](#Tab2){ref-type="table"}) should be offered treatment.Table 2Updated 2018 International Workshop on CLL (IWCLL) guidelines to initiate CLL therapy^[@CR5]^Any **one** of the following criteria should be met to initiate CLL therapy:• Progressive marrow failure, hemoglobin \<10 gm/dL or platelet count of \<100 × 10^9^/L• Massive (≥6 cm below the left costal margin) or progressive or symptomatic splenomegaly• Massive (≥10 cm in longest diameter) or progressive or symptomatic lymphadenopathy• Progressive lymphocytosis with an increase of ≥50% over a 2-month period or lymphocyte doubling time of \<6 months• Autoimmune complications of CLL, that are poorly responsive to corticosteroids• Symptomatic extranodal involvement (e.g., skin, kidney, lung, spine)• Disease-related symptoms, including: ◦ Unintentional weight loss of ≥10% within the previous 6 months ◦ Significant fatigue ◦ Fever ≥38 °C for 2 or more weeks without evidence of infection ◦ Night sweats for ≥1 month without evidence of infection

Patients who do **not** meet the 2018 IWCLL criteria for therapy {#Sec4}
----------------------------------------------------------------

Figure [1](#Fig1){ref-type="fig"} shows a suggested approach to the management of patients who do not meet the 2018 IWCLL criteria for therapy. All patients should undergo risk stratification according to the CLL-IPI at the time of diagnosis. Patients in the low- and intermediate-risk category CLL-IPI (\~75% patients, median time to first therapy \~7 years) should be monitored for disease progression every 6--12 months. Patients in the high- and very high-risk CLL-IPI group (\~25% patients, median time to first therapy \~2 years) should be monitored for disease progression every 3--6 months^[@CR30]^. Regardless of the CLL-IPI score, all patients should be counseled for (a) increased risk of infections; with special attention to appropriate vaccinations according to the Centers for Disease Control and Prevention (CDC) guidelines^[@CR37]^; (b) increased risk of non-hematologic malignancy, and recommendations to follow age-appropriate cancer screening; and (c) increased risk of skin cancers, with yearly full body skin exam by dermatology^[@CR38],[@CR39]^. Patients with high- and very high-risk CLL may be offered treatment in early intervention clinical trials. The German CLL study group is conducting a phase 3 study (CLL12 trial) that randomizes patients with asymptomatic high-risk disease to ibrutinib vs. placebo; efficacy results from this trial are not available yet^[@CR40]^. An important caveat to performing prognostic testing in *all* patients with newly diagnosed early-stage CLL is that this information may not be necessarily helpful in patients with advanced age, poor performance status, multiple co-morbidities, or those with limited life expectancy. Therefore, practicing oncologists must exercise their clinical judgment in obtaining these tests in newly diagnosed CLL patients who do not meet indications for therapy.Fig. 1Suggested approach to the management of patients with newly diagnosed CLL who do not meet the 2018 IWCLL criteria for therapy

Patients who meet the 2018 IWCLL criteria to start therapy {#Sec5}
----------------------------------------------------------

It should be noted that all patients who meet the 2018 IWCLL criteria should be offered therapy, regardless of their CLL-IPI risk group assignment. When feasible, all patients should be offered participation in well-designed clinical trials. Figure [2](#Fig2){ref-type="fig"} shows a suggested approach for the management of previously untreated CLL patients, outside the context of clinical trials.Fig. 2Suggested approach to the management of patients with previously untreated CLL who meet the 2018 IWCLL criteria for therapy (outside the context of clinical trials)

### Ascertain the *TP53* status prior to therapy {#Sec6}

The *TP53* status is one of the most important prognostic and predictive biomarkers in CLL. This should be ascertained using (a) CLL FISH panel to look for evidence of del17p13 and (b) Sanger sequencing or next-generation sequencing panel to evaluate for *TP53* mutations, with a cutoff of at least 10%. It is important to obtain both these tests, since \~3--5% patients will harbor a deleterious *TP53* mutation on DNA sequencing in the absence of del17p13 on CLL FISH; and multiple studies have shown these patients have equally poor outcomes^[@CR19],[@CR41]--[@CR43]^. Patients with *TP53* disruption have a short PFS and OS when treated with standard chemoimmunotherapy regimens such as FCR and BR, and are therefore not recommended for these patients^[@CR7],[@CR44]^. In contrast, a single-arm phase 2 study of ibrutinib in previously untreated CLL patients with *TP53* disruption showed the overall response rate (ORR) was 97%, the cumulative incidence of progression at 2-years was 9%, and the estimated 2-year OS was 84%^[@CR45]^. The unprecedented response rates and excellent outcomes make ibrutinib the treatment of choice in this group of patients. All patients with *TP53* mutation who need treatment should be referred to a cellular therapy expert, to discuss potential treatment options with either an allogeneic stem cell transplant or chimeric antigen receptor T-cell (CAR-T) therapy.

### Ascertain the *IGHV* mutation status and fitness of the patient {#Sec7}

Several studies have shown that *IGHV* mutated patients who receive FCR experience a long PFS (that can exceed 10 years)---making this an important treatment choice in patients who have no evidence of *TP53* disruption^[@CR46]--[@CR48]^. Treatment with FCR is recommended only in young (generally \<65 years) and otherwise fit patients who are able to tolerate this intensive regimen. The CLL8 trial (phase 3 study comparing FCR to fludarabine and cyclophosphamide in previously untreated CLL) showed the ORR was 90% (complete response \[CR\] in 40% patients), and the median PFS was 52 months (the median PFS was not reached for the subset of *IGHV* mutated patients after a median follow-up of \~6 years)^[@CR44],[@CR46]^. Long-term follow-up of the MDACC phase 2 FCR data show that after a median follow-up of \~13 years, the risk of secondary myeloid neoplasms was \~5% and of Richter's transformation was \~8%^[@CR47]^. A retrospective study from MD Anderson Cancer Center reported that patients who are MRD negative in the bone marrow at the end of 3 cycles of FCR therapy have similar long-term outcomes compared to patients who receive 6 cycles of therapy, suggesting it may be possible to avoid the cumulative toxicity that is frequently seen with this regimen^[@CR34]^. The CLL10 trial (phase 3 trial comparing FCR to bendamustine and rituximab in previously untreated CLL) showed that therapy with FCR was associated with a higher CR rate (40% vs. 31%, *p* = 0.03) and a longer PFS compared to BR (55 months vs. 42 months, *p* \< 0.001); although in the subset of patients \>65 years of age, FCR led to more infectious and hematologic toxicities^[@CR7]^.

For patients who are older and frail or have comorbidities (cumulative rating illness score \[CIRS\] of ≥7), therapy with chlorambucil and obinutuzumab (a humanized type II CD20 monoclonal antibody with a glycoengineered Fc domain) showed higher ORR (78% vs. 65%, *p* \< 0.001) and longer PFS (median 29 months vs. 15 months, *p* \< 0.001) compared to chlorambucil and rituximab in the CLL11 trial^[@CR49]^. Since chlorambucil is frequently associated with significant myelosuppression and gastrointestinal toxicity, obinutuzumab as a single-agent may be used without loss of efficacy^[@CR50]^. The RESONATE-2 trial compared ibrutinib to chlorambucil in elderly CLL patients (≥65 years; 69% CIRS score \>6, del17p patients excluded), and showed that after a median follow-up of \~18 months, the estimated median PFS was not reached in the ibrutinib arm compared to 18.9 months in the chlorambucil arm. Ibrutinib also improved OS significantly; the estimated 24-month OS in the ibrutinib arm was 98% compared to 85% in the chlorambucil arm (despite crossover). The improvement in PFS and OS was similar among *IGHV* mutated and unmutated patients, indicating that ibrutinib was able to ameliorate the inferior outcomes of chemoimmunotherapy treated patients with unmutated *IGHV* genes^[@CR51]^.

Two major phase 3 intergroup studies (ECOG 1912 \[comparing FCR to ibrutinib and rituximab\] and the ALLIANCE 041202 \[comparing BR to ibrutinib and ibrutinib/rituximab\]), and the CLL 14 trial (comparing venetoclax/obinutuzumab to chlorambucil/obinutuzumab) have completed accrual, and results from these trials will inform future practice in the frontline setting. Until the results of these trials are available, chemoimmunotherapy with FCR (\<65 years) or BR (≥65 years) may be appropriate for young fit patients who have mutated *IGHV* genes. Among young fit patients with unmutated *IGHV* genes, ibrutinib is preferred in patients with an unfavorable FISH profile (such as del11q), whereas FCR and BR can be used in patients with standard risk FISH (del13q, normal and +12). Although both ibrutinib and obinutuzumab (with or without chlorambucil) may be used in old frail patients regardless of their *IGHV* mutation status, ibrutinib is preferred among those with unmutated *IGHV* genes. Patient preference plays a very important role in choosing therapy, where some patients prefer time-limited chemoimmunotherapy compared to daily oral continuous therapy with novel agents. Also, many patients have significant out of pocket costs for novel oral agents (financial toxicity), whereas infusional therapy may be completely covered by their insurance, making patients choose one type of treatment over another. A final recommendation regarding therapy should take into consideration all of these issues.

Unlike other chronic lymphoproliferative neoplasms, there is a limited role of maintenance therapy in CLL. Compared to placebo, maintenance therapy with lenalidomide prolonged PFS (but not OS) after both first-line and subsequent-line chemoimmunotherapy in CLL^[@CR52],[@CR53]^. However, these trials enrolled high-risk patients (such as those with unmutated *IGHV* genes and high-risk cytogenetics by FISH), who would be treated with novel agents to begin with, making these results less pertinent in the current era.

Treatment of relapsed/refractory CLL {#Sec8}
====================================

All patients who have relapsed CLL should undergo a comprehensive assessment of their disease status, including a bone marrow aspirate and biopsy, and a CT scan of the chest, abdomen, and pelvis (a positron emission tomography \[PET\] scan is preferred if there is suspicion for Richter's transformation). Also, all patients should have a CLL FISH panel and at minimum *TP53* mutation status re-analyzed prior to starting therapy. Although the *TP53* disruption status may not impact treatment choice given that all novel agents have excellent efficacy in this group of patients, the frequency of follow-up, monitoring for progression of disease, and the anticipated PFS benefit will be different in patients with *TP53* disruption compared to patients with intact *TP53*.

Chemoimmunotherapy plays a less important role in the contemporary management of relapsed/refractory CLL. Circumstances where chemoimmunotherapy may be preferred include: patient preference, prohibitive cost of the novel agents, significant comorbidities that preclude the use of novel agents or if the patient has had a long (\>3--5 years) remission duration after the first therapy. Several trials have compared the combination of a novel agent and chemoimmunotherapy to chemoimmunotherapy alone (such as ibrutinib/BR compared to BR \[HELIOS\]^[@CR54]^, idelalisib/BR compared to BR)^[@CR55]^ in relapsed/refractory CLL. Unfortunately, these studies lack the novel agent alone as a comparator arm, and therefore it is difficult to draw conclusions for routine practice from these studies. Figure [3](#Fig3){ref-type="fig"} shows a suggested approach to the management of relapsed/refractory CLL, outside the context of clinical trials.Fig. 3Suggested approach to the management of patients with relapsed/refractory CLL (outside the context of clinical trials)

Relapsed/refractory CLL that is naive to ibrutinib {#Sec9}
--------------------------------------------------

Multiple clinical trials have confirmed the efficacy and safety of ibrutinib in relapsed CLL, among patients with and without *TP53* disruption. The pivotal RESONATE trial compared ibrutinib to ofatumumab in 391 patients with relapsed CLL (median number of prior therapies = 3). After a median follow-up of 9.4 months, the median PFS was not reached in the ibrutinib arm compared to 8.1 months in the ofatumumab arm (*p* \< 0.001). Ibrutinib also significantly improved OS (12-month OS: 90% for ibrutinib vs. 81% for ofatumumab, hazard ratio for death, 0.43; *p* = 0.005). Similar results were seen among ibrutinib-treated patients with del17p13 and purine nucleoside analog refractory disease, who historically have poor outcomes^[@CR56]^. Extended follow-up of the RESONATE study (median 19 months) showed that the estimated PFS at 24 months in the ibrutinib arm was 74%^[@CR57]^. Five-year follow-up data from the single-arm phase 2 PCYC-1102/1103 study in which 101 relapsed/refractory CLL patients were treated with ibrutinib, the 5-year PFS was 44% (the median PFS by cytogenetic group according to FISH was 26 months for del17p13; 51 months for del11q23; and not reached for the other groups)^[@CR58]^. A randomized study comparing ibrutinib to the combination of ibrutinib and rituximab in both previously untreated and relapsed/refractory CLL failed to show any incremental benefit of the addition of rituximab (2-year PFS in both groups was \~90%); suggesting that until more data become available, single-agent ibrutinib should be used in all patients^[@CR59]^. The only exception may be in patients where a rapid response to treatment is desired, since the median time to normalization of the absolute lymphocyte count and MRD negative complete remission was shorter in the ibrutinib/rituximab arm.

The most common non-hematologic toxicities (≥grade 3) reported in the ibrutinib arm of RESONATE trial include pneumonia (10%), diarrhea (5%), fatigue (4%), and arthralgia (2%). Other toxicities include hypertension (\~15%), atrial fibrillation (\~10%), and major bleeding (\~7%)^[@CR56]^. Additionally, with longer follow-up, other adverse events, such as disseminated zoster^[@CR60]^, *Pneumocystis jirovecci* pneumonia^[@CR61]^ and invasive aspergillosis^[@CR62]^ have been reported with ibrutinib use. In contrast to patients treated on clinical trials, data from patients treated in the context of routine clinical practice show that \~40% patients discontinue ibrutinib after \~2 years on therapy; the vast majority due to toxicity/intolerance^[@CR63],[@CR64]^. For a detailed discussion of the practical considerations about patients receiving ibrutinib therapy, I would refer the reader to these excellent articles published recently^[@CR65],[@CR66]^. An integrated analysis of \~300 CLL patients treated with ibrutinib at The Ohio State University showed that younger age, complex karyotype, and del17p13 were most commonly associated with CLL progression^[@CR67]^.

Venetoclax has shown promising efficacy in the treatment of patients with relapsed CLL. In a phase 1b/2 study of venetoclax in relapsed/refractory CLL (*n* = 116, median number of prior therapies = 4), the ORR was 82%, and the estimated 15-month PFS was \~70% (at the recommended phase 2 dose level of 400 mg daily)^[@CR10]^. In another study of single-agent venetoclax in 107 relapsed CLL patients with del17p13, the ORR was 79% and the estimated 12-month PFS was 72%^[@CR68]^. On the basis of these results, venetoclax was Food and Drug Administration (FDA) approved for the treatment of relapsed/refractory CLL with del17p13. The MURANO study is a large phase 3 trial that compared venetoclax/rituximab to bendamustine/rituximab in patients with relapsed CLL (*n* = 389, including del17p13). After a median follow-up of \~2 years, the 2-year PFS was 85% in the venetoclax/rituximab arm compared to 36% in the bendamustine/rituximab arm (HR for progression or death: 0.17, *p* \< 0.001). These results were consistent across patient subgroups; additionally, the rates of MRD negative status in the peripheral blood were significantly higher in the venetoclax/rituximab arm compared to bendamustine/rituximab (83% vs. 23%), suggesting that combination therapy with venetoclax and rituximab can achieve deep remissions even in patients with high-risk features^[@CR36]^.

The most common side-effects of venetoclax are neutropenia (occurring in \~50% patients, which can be mitigated with growth factor support); tumor lysis syndrome (for which a gradual ramp-up dosing schema should be followed as specified in the package insert); and serious infections. In an analysis of 67 patients with relapsed CLL treated with single-agent venetoclax, fludarabine refractoriness and complex karyotype were associated with progression, whereas del17p13 or *TP53* mutations were not^[@CR69]^. Longer follow-up with larger cohorts of patients will be necessary to determine which patients are most likely to experience disease progression on venetoclax.

Single-agent venetoclax is approved by the FDA for patients with relapsed/refractory CLL who have del17p by FISH. The combination of venetoclax and rituximab was recently approved by the FDA for *all* patients with relapsed/refractory CLL (regardless of the CLL FISH findings). However, given the lack of randomized trials comparing ibrutinib to venetoclax, the initial choice between these agents in relapsed CLL depends on patient comorbidities. In patients who have significant cardiovascular disease, are receiving anticoagulant therapy or have a high risk of bleeding, venetoclax may be more appropriate than ibrutinib. On the other hand, patients with significant tumor bulk (\>10 cm lymph nodes) are at significant risk for developing tumor lysis syndrome with venetoclax, and ibrutinib may be more appropriate for this group of patients. It should be noted that these considerations for choosing ibrutinib vs. venetoclax are not absolute, and practicing oncologists may choose one over the other. Cross trial comparisons indicate patients who are treated with venetoclax (particularly in combination with rituximab) may achieve MRD negative complete remission sooner than those treated with ibrutinib as a single-agent, which would allow for patients to discontinue therapy. However, at this time, the data regarding discontinuation of novel agents in CLL patients who have achieved MRD negative complete remission are non-existent, and should therefore not impact the decision to start one type of treatment over another. Data regarding acquired resistance to ibrutinib (with the emergence of mutations in *BTK* and *PLCγ2* genes)^[@CR67]^ and venetoclax (mutations in *BTG1* and homozygous deletions in *CDKN2A/B*)^[@CR70]^ will allow earlier detection of sub-clinical relapse, and more targeted interventions to improve outcomes in patients with relapsed disease.

The combination of idelalisib and rituximab is also approved for the treatment of relapsed CLL^[@CR9]^. However, idelalisib is associated with ≥grade 3 toxicity including colitis, transaminitis, and pneumonitis, in addition to infectious complications such as reactivation of cytomegalovirus and *P. jirovecii* pneumonia, making it less attractive if other options are available. Other novel agents with ongoing phase 3 trials in relapsed CLL include acalabrutinib, duvelisib, and umbralisib, among others; however, these are not approved for relapsed CLL at this time. Finally, many exciting combination studies of novel agents and monoclonal antibodies (doublet or triplet regimens) are currently being evaluated in relapsed CLL to achieve higher MRD negative complete remissions with the goal of discontinuing therapy, and results of these trials are eagerly awaited.

Relapsed/refractory CLL progressing on ibrutinib {#Sec10}
------------------------------------------------

CLL patients who have progressive disease on ibrutinib represent a significant challenge, since many have rapid progression of the disease and experience poor outcomes^[@CR71]^. It is critical to distinguish Richter's transformation from progressive CLL in these patients. In a comprehensive analysis of risk factors for progression among \~300 ibrutinib-treated CLL patients, complex karyotype and BCL-6 abnormality were associated with Richter's transformation^[@CR67]^. More importantly, Richter's transformation typically occurred in the first year whereas CLL progression events occurred in the second year of ibrutinib therapy. Unfortunately, the predictive ability of a PET scan in distinguishing Richter's transformation from CLL progression in the era of novel agents is not very clear. In an analysis of 167 CLL patient progressing on BTK inhibitors, a standardized uptake value (SUV) cut-off of 10 was associated with poor sensitivity and specificity in predicting Richter's transformation^[@CR72]^. Therefore, all patients with rapidly proliferating disease (particularly in the first year on ibrutinib therapy), along with a high lactate dehydrogenase, should undergo a PET scan and an excisional or core needle biopsy of the most PET avid lymph node to ascertain Richter's transformation.

In an analysis of 91 patients who were either refractory to or had intolerance to ibrutinib therapy, venetoclax was associated with an ORR of 65% (9% CR rate) and a median time to progression of \~24 months^[@CR73]^. Data from a large cohort of CLL patients who were treated in routine clinical practice (i.e., outside the context of a clinical trial) also support the use of venetoclax in patients who progress on or have intolerance to ibrutinib, as opposed to using idelalisib and rituximab^[@CR74]^. Unfortunately, given the low CR rate with single-agent venetoclax, it will be necessary to use combination strategies with either an anti-CD20 monoclonal antibody therapy or other novel agents. Many patients experience rapid disease progression when ibrutinib is stopped (since the dose ramp up to the approved daily therapeutic dose of 400 mg venetoclax takes \~5 weeks). Although no formal guidelines are available in such a situation, two possible approaches seem reasonable: (a) follow an accelerated ramp up dosing schedule of venetoclax (20 mg on day 1, 50 mg daily on days 2 and 3, 100 mg daily on days 4--7, 200 mg daily on days 8--14, and then 400 mg daily); or (b) continue with ibrutinib until the target dose of venetoclax is reached.

CAR-T cell therapy has also shown remarkable efficacy in the management of CLL patients who have disease progression on ibrutinib. In a study of 27 relapsed/refractory CLL patients (19 of whom had progression of disease on ibrutinib), anti-CD19 CAR-T cell therapy was associated with an ORR of 74% at 4 weeks, with a CR rate of 21%. Twenty patients (83%) developed cytokine release syndrome and eight (33%) developed neurotoxicity (which was reversible in all but one patient who had a fatal outcome). The median PFS was \~9 months and the median OS was not reached---none of the responding patients proceeded to an allogeneic stem cell transplant^[@CR75]^. Although these results are encouraging, anti-CD19 CAR-T cell therapy is not approved for relapsed CLL yet, and therefore it is challenging to use this approach outside the context of clinical trials.

Special situations {#Sec11}
==================

Richter's transformation is the development of an aggressive B-cell neoplasm in CLL patients (the most common histology is diffuse large B-cell lymphoma (DLBCL) followed by Hodgkin lymphoma)^[@CR1]^. A comprehensive review of the risk factors and management is outside the scope of this article; I would refer the readers to an excellent review published recently^[@CR76]^. Among patients who develop DLBCL, establishing the clonal relationship between the DLBCL and CLL clone has important prognostic implications (patients with clonally unrelated DLBCL have much better outcomes than those that are clonally related)^[@CR77],[@CR78]^. Among patients with Richter's transformation who have not received prior CLL therapy or are clonally unrelated, multi-agent cytotoxic therapy with either (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone \[R-CHOP\]) or infusional dose-adjusted etoposide, doxorubicin, and cyclophosphamide with vincristine, prednisone, and rituximab (DA-EPOCH-R) may be appropriate first-line therapy. For patients who develop transformation after ibrutinib or among patients with clonally related DLBCL where there is evidence of *TP53* disruption or *NOTCH1* mutation, PD1 inhibitor therapy with pembrolizumab and nivolumab has shown promising results^[@CR79],[@CR80]^. Consolidation with an allogeneic SCT (or autologous SCT in patients where no matched donor is available) has shown to improve outcomes in this difficult-to-treat complication of CLL^[@CR81]^. Therapy with adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) remains the standard of care for patients with Hodgkin transformation of CLL. Although the outcomes of Hodgkin transformation in CLL are better than patients who develop DLBCL transformation, these patients do significantly worse compared to those with de novo Hodgkin lymphoma^[@CR82]^.

Autoimmune cytopenias occur in \~5--10% CLL patients (most commonly autoimmune hemolytic anemia \[AIHA\] and immune thrombocytopenia)^[@CR83]^. In the absence of significant CLL tumor burden, these should be treated with corticosteroids or single-agent rituximab. In patients where CLL therapy is indicated or in whom the autoimmune cytopenias are refractory to first-line therapy, the general approach to the management of CLL patients as outlined above should be followed. Fludarabine (as a single-agent) can exacerbate hemolytic anemia in CLL and should be avoided in patients with a history of AIHA. FCR should be used with caution in CLL patients with a history of AIHA, although this remains a controversial issue. There is limited information on the use of ibrutinib in the treatment of autoimmune cytopenias in CLL (since the vast majority of clinical trials excluded patients with uncontrolled autoimmune cytopenias), although there is emerging evidence that it may be safe to do so^[@CR84],[@CR85]^.

Conclusion {#Sec12}
==========

There has been substantial progress in the management of CLL patients in the past decade. With the introduction of novel agents such as ibrutinib, idelalisib, and venetoclax, the role of chemoimmunotherapy in the treatment of CLL is being re-examined in the current era. Pressing questions in the next phase of CLL research include how best to combine novel agents, the sequencing of these treatments, and administering time-limited treatments to achieve deep remissions that allow stopping therapy.
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